Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2017; 8(3):388-394. doi:10.7150/jca.16804 This issue Cite

Research Paper

Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients

Wen-Zhuo He*, Fang-Xin Liao*, Chang Jiang, Peng-Fei Kong, Chen-Xi Yin, Qiong Yang, Hui-Juan Qiu, Bei Zhang, Liang-Ping Xia✉

VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
*Wen-Zhuo He and Fang-Xin Liao contributed equally to this paper.

✉ Corresponding author: Liang-Ping Xia. Email: xialiangpingcom; Fax: +8620-87343392; Tel: +8620-87343107; Mobile: 13926410608. Addresses: Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovat More

Citation:
He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP. Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J Cancer 2017; 8(3):388-394. doi:10.7150/jca.16804. https://www.jcancer.org/v08p0388.htm
Other styles

File import instruction

Abstract

Background: Published papers reported contradictory results about the correlation between bevacizumab effectiveness and primary tumor location of metastatic colorectal cancer (mCRC).

Methods: 740 mCRC patients treated with chemotherapy (CT group) and 244 patients treated with bevacizumab plus chemotherapy as first-line setting (CT + B group) were included. Propensity score analyses were used for patients' stratification and matching. Kaplan-Meier curves with log-rank tests were used to detect different overall survival (OS).

Results: Patients in CT + B group had similar OS comparing with CT group only when the primary tumor located at right-side colon (20.2 for CT + B versus 19.7 months for CT group, p = 0.269). For left-side colon and rectal cancer patients, significantly longer OS were observed in CT + B than CT group.

Conclusion: Our data suggested only patients with left-side colon or rectal cancer could get survival benefit from the addition of bevacizumab to first-line chemotherapy.

Keywords: Colorectal cancer, metastasis, prognosis, bevacizumab, and location.

Citation styles

APA
He, W.Z., Liao, F.X., Jiang, C., Kong, P.F., Yin, C.X., Yang, Q., Qiu, H.J., Zhang, B., Xia, L.P. (2017). Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. Journal of Cancer, 8(3), 388-394. https://doi.org/10.7150/jca.16804.

ACS
He, W.Z.; Liao, F.X.; Jiang, C.; Kong, P.F.; Yin, C.X.; Yang, Q.; Qiu, H.J.; Zhang, B.; Xia, L.P. Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J. Cancer 2017, 8 (3), 388-394. DOI: 10.7150/jca.16804.

NLM
He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP. Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J Cancer 2017; 8(3):388-394. doi:10.7150/jca.16804. https://www.jcancer.org/v08p0388.htm

CSE
He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP. 2017. Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J Cancer. 8(3):388-394.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use